Higher BMI is associated with poorer fertility prognosis, and many studies have shown that obesity is associated with increased time-to-pregnancy. Obesity is frequently associated with metabolic syndrome – a cluster of factors including insulin resistance, glucose intolerance, dyslipidemia, and hypertension. The successful use of GLP-1 agonists for weight loss, HgbA1c reduction, decrease in blood pressure, and improvement in dyslipidemia has been well established. There is an emerging role for the use of GLP-1 agonists to increase fertility rates among reproductive-age women.